Bio-Techne Corporation

Equities

TECH

US09073M1045

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:21:16 15/05/2024 BST			5-day change	1st Jan Change
83.43 ^USD	-0.86%		+8.22%	+8.06%

05-06	Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating	MT
05-02	UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating	MT

Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2024, Payable on May 24, 2024

May 01, 2024 at 11:30 am

Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2024. The quarterly dividend will be payable May 24, 2024, to all common shareholders of record on May 13, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Latest news about Bio-Techne Corporation

Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating	05-06	MT
UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating	05-02	MT
Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85	05-02	MT
Scotiabank Adjusts Price Target on Bio-Techne to $83 From $80	05-02	MT
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept	05-02	MT
Baird Adjusts Bio-Techne Price Target to $81 From $73	05-02	MT
Equity Markets Mostly Fall After Fed Leaves Rate Unchanged	05-01	MT
Equity Markets Mostly Fall After Fed Leaves Rate Unchanged	05-01	MT
Top Midday Gainers	05-01	MT
US Equity Indexes Mixed as Investors Look for Clarity in Fed's Policy Path in Presidential Election Year	05-01	MT
US Equity Indexes Mixed Ahead of Fed Policy Statement, Views on Monetary Policy Path for 2024	05-01	MT
Bio-Techne Shares Jump After Fiscal Q3 Beat	05-01	MT
Deutsche Bank Adjusts Price Target on Bio-Techne to $84 From $82	05-01	MT
Transcript : Bio-Techne Corporation, Q3 2024 Earnings Call, May 01, 2024	05-01
Bio-Techne's Fiscal Q3 Adjusted Earnings Fall, Net Sales Rise	05-01	MT
Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q3 Revenue $303.4M	05-01	MT
Bio-Techne Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-01	CI
Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2024, Payable on May 24, 2024	05-01	CI
Bio-Techne Corporation Appoints Dr. Judith Klimovsky to Board of Directors	04-30	CI
Bio-Techne to Enter Product Distribution Deal With Thermo Fisher Scientific	04-29	MT
RBC Capital Adjusts Price Target on Bio-Techne to $71 From $79	04-29	MT
Bio-Techne Corporation Announces New Distribution Agreement with Thermo Fisher Scientific	04-29	CI
Bio-Techne Corporation and Novomol-Dx Announce Point-of-Care Ocular Biomarker Assay	04-26	CI
Bio-Techne Says It Filed Patent Infringement Lawsuit Against Molecular Instruments in Europe	04-23	MT
Deutsche Bank Adjusts Bio-Techne Price Target to $82 From $85	04-18	MT

Chart Bio-Techne Corporation

Duration

Period

More charts

Company Profile

Bio-Techne Corporation specializes in the manufacture and marketing of products used in life science research. The group offers reagents and diagnostic tools for researchers, doctors, laboratories, pharmaceutical and biotechnology companies, etc. Net sales break down by family of products as follows: - biological and chemical reagents and analysis tools (74.3%): proteins, antibodies, molecules, culture serums, tools for cell work, tools for the study of proteins, immunoassay tools, etc.; - diagnostic and genomics products (25.7%): reagents and products used in blood analysis, nucleic acid analysis, tissue biopsy, gene analysis, cancer and genetic carrier screening, etc. Net sales are distributed geographically as follows: the United States (56.5%), the United Kingdom (4.4%), Europe/Middle East/Africa (19.4%), China (10%), Asia/Pacific (6.4%), and other (3.3%).

Sector

Biotechnology & Medical Research

Calendar

20/05/2024 - Benchmark Healthcare House Virtual Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Bio-Techne Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

84.15 USD

Average target price

83.64 USD

Spread / Average Target

-0.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIO-TECHNE CORPORATION	+8.06%	13.26B
MODERNA, INC.	+28.99%	49.18B
IQVIA HOLDINGS INC.	+0.82%	42.11B
LONZA GROUP AG	+50.47%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.63%	18.71B
MEDPACE HOLDINGS, INC.	+32.17%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.52%	11.99B
UNITED THERAPEUTICS CORPORATION	+24.26%	11.97B

Other Biotechnology & Medical Research